CD274 and esophageal cancer: Several phase III trials [12, 13, 15, 16] have demonstrated that, compared with CT, inhibitors of programmed death receptor 1 (PD-1) and its ligand, PD-L1, were associated with significant longer overall survival (OS) and a manageable safety profile in previously treated patients with advanced esophageal cancer.